查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985523

肺癌基因組檢測市場：依技術、檢測類型、應用和最終用戶分類－2026-2032年全球市場預測

Lung Cancer Genomic Testing Market by Technology, Test Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺癌基因組檢測市場價值將達到 11.6 億美元，到 2026 年將成長到 12.6 億美元，到 2032 年將達到 20.7 億美元，複合年成長率為 8.58%。

主要市場統計數據
基準年 2025 11.6億美元
預計年份：2026年 12.6億美元
預測年份 2032 20.7億美元
複合年成長率 (%) 8.58%

全面概述了技術進步及其在臨床實踐中的應用如何重新定義肺癌基因組檢測並塑造治療路徑。

目前，肺癌基因組檢測正處於臨床緊迫性和技術能力的交匯點，它正在重塑診斷、治療方案製定和轉化研究。隨著分子層面的洞察力日益成為標靶治療治療和免疫療法適用性的關鍵因素，臨床醫生和檢查室正在採用基因組檢測，從基於組織學的診療模式轉向以精準醫學主導的治療路徑。因此，病理學、分子生物學、生物資訊學和臨床腫瘤學等以往各自獨立的領域正在融合，從而構建出整合的診療路徑，縮短患者接受標靶治療的時間，並實現更精準的患者分層。

定序、液態生物檢體和數位生物資訊學的融合如何迅速改變肺癌治療的診斷途徑和患者管理。

肺癌基因組檢測領域正經歷多項變革，主要得益於檢測技術、數據分析和醫療服務模式的進步。尤其值得一提的是，次世代定序已從高成本、以研究為導向的工作流程，發展成為更高效、經臨床檢驗的平台，支持透過全外EXOME和全基因組方法以及靶向定序panel實現廣泛的基因組覆蓋。這項進展使臨床醫生能夠檢測到罕見突變和全面的基因組特徵，同時檢查室也能最佳化處理能力和反應時間。

近期關稅壓力對供應鏈的影響如何重塑了基因組診斷領域的採購、製造策略和商業性模式。

近期各國政策制定者實施的關稅調整，使得診斷生態系內的供應鏈韌性與籌資策略再次受到重視。由於基因組檢測依賴全球供應鏈取得試劑、定序設備、塑膠耗材和專用微流體組件，因此關稅導致的成本增加會對檢查室營運、試劑採購週期和資本設備購置決策產生連鎖反應。因此，檢查室和診斷服務提供者必須重新評估供應商合約、庫存策略和資本投資計劃，以確保服務的連續性並維持可接受的檢測結果回應時間。

以細分市場為中心的洞察，展示了技術選擇、檢體模式、臨床應用和最終用戶能力如何共同決定採用路徑和價值提案。

從詳細的市場細分觀點，不同技術、檢測類型、應用和終端用戶類別之間的引入模式呈現出微妙的變化，從而塑造了市場機會和投資重點。從技術層面來看，檢測方法涵蓋了螢光原位雜合反應、微陣列平台、即時聚合酵素鏈鎖反應和桑格定序等。然而，次世代定序正迅速崛起，成為一項至關重要的技術，其配置也多種多樣。這些配置包括針對特定可操作突變的標靶定序panel、用於全面分析轉錄區的全EXOME定序，以及用於檢測最廣泛的突變並獲得結構資訊的全基因測序。每種配置在靈敏度、覆蓋範圍、週轉時間和結果解讀的複雜度方面都各有優劣。

影響技術採用、償還努力和策略夥伴關係的區域部署趨勢和基礎設施考量。

區域趨勢對技術應用、監管協調和商業策略產生了重大影響，美洲、歐洲、中東和非洲以及亞太地區呈現不同的模式。在美洲，由學術機構、綜合醫療保健系統和診斷技術創新者組成的強大生態系統推動了先進基因組分析和液態生物檢體檢測的早期臨床應用。該地區的報銷框架和大規模臨床研究正在促進伴隨診斷融入治療路徑，同時領先的實驗室和商業合作夥伴也持續投資於平台擴充性和臨床檢驗計畫。

定序設備製造商、試劑供應商、診斷檢測實驗室和生物製藥合作夥伴如何協調其策略以實現臨床准入和商業性差異化。

肺癌基因組檢測價值鏈的競爭主要集中在以下幾類公司之間：提供定序平台、檢測試劑、綜合診斷服務和臨床解讀解決方案的公司，以及將檢測和治療方案結合的臨床實驗室和診斷開發公司。領先的儀器供應商正致力於制定以通量、運行成本和整合分析能力為重點的平台藍圖，而試劑和試劑盒供應商則在穩健性、批間一致性和簡化監管申報和檢查室認證流程的臨床檢驗方案方面展開競爭。

為企業提供切實可行的建議，以增強供應鏈韌性，加快證據生成，並確保與支付方和合作夥伴合作，以實現永續成長。

產業領導企業應優先採取一系列切實可行、以證據為基礎的措施，在應對技術複雜性、政策變化和市場壓力的同時，創造臨床和商業性價值。首先，他們必須實現價值鏈多元化，並透過本地化生產和對關稅敏感的試劑和耗材採用第二供應商合約來穩定採購成本。同時，他們應投資於檢測方法最佳化，以最大限度地減少試劑用量並簡化工作流程，從而保持盈利能力和韌性。

透明、多方面的研究途徑，結合與專家的直接參與和系統性的證據審查，確保了嚴謹且可操作的見解。

本分析的基礎研究採用了一種多方面的方法，將一手定性研究與系統的二手資訊分析相結合，建構了一個穩健且多方驗證的證據基礎。一手研究包括對臨床實驗室管理人員、分子病理學家、醫保報銷專家、診斷藥物研發人員以及製藥公司研發負責人進行結構化訪談，並輔以專家專題研討會，以檢驗檢測實施中的新興趨勢和實際挑戰。這些工作深入分析了檢查室工作流程、採購趨勢以及監管和關稅變化對營運的影響。

簡要概述如何將技術進步與策略挑戰相結合，並將基因組檢測轉化為永續的臨床和商業性影響。

先進定序技術、液態生物檢體創新和數位化分析工具的融合，為肺癌基因組檢測的臨床格局帶來了不可逆轉的改變。這些進步既帶來了機遇，也帶來了挑戰。機會包括能夠更精準地選擇治療方法、支持適應性臨床試驗以及透過微創檢測實現時間序列監測。另一方面，挑戰包括需要策略遠見的供應鏈管理、證據產生以及與保險公司的合作。因此，決策者必須採取綜合觀點，協調技術投資、臨床檢驗和商業性部署。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肺癌基因組檢測市場：依技術分類

  • 螢光原位雜合反應
  • 微陣列
  • 次世代定序
    • 目標序列
    • 全EXOME定序
    • 全基因組定序
  • 即時聚合酵素鏈鎖反應
  • 桑格定序

第9章 肺癌基因組檢測市場：檢測類型

  • 液態生物檢體
    • 循環性腫瘤細胞
    • 循環腫瘤DNA
  • 組織切片檢查
    • 細針穿刺
    • 組織切片

第10章：肺癌基因組檢測市場：依應用領域分類

  • 伴隨診斷
  • 預測性測試
  • 預後檢查
  • 治療監測

第11章 肺癌基因組檢測市場：依最終用戶分類

  • 學術研究機構
  • 醫院和診斷檢測實驗室
  • 製藥和生物技術公司

第12章 肺癌基因組檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 肺癌基因組檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 肺癌基因組檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國肺癌基因組檢測市場

第16章：中國肺癌基因組檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Admera Health
  • Agilent Technologies, Inc.
  • BGI
  • CD Genomics
  • CeGaT GmbH
  • Centogene NV
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
  • OncoDNA
  • OPKO Health, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific, Inc.
  • Veracyte, Inc.
Product Code: MRR-7C31448F0BA8

The Lung Cancer Genomic Testing Market was valued at USD 1.16 billion in 2025 and is projected to grow to USD 1.26 billion in 2026, with a CAGR of 8.58%, reaching USD 2.07 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.16 billion
Estimated Year [2026] USD 1.26 billion
Forecast Year [2032] USD 2.07 billion
CAGR (%) 8.58%

A comprehensive orientation to how technological advances and clinical integration are redefining lung cancer genomic testing and shaping care pathways

Lung cancer genomic testing now sits at the intersection of clinical urgency and technological capability, reshaping diagnostics, therapeutic decision-making, and translational research. As molecular insights increasingly determine targeted therapies and immunotherapy candidacy, clinicians and laboratories are adopting genomic assays to move from histology-based care to precision-guided treatment pathways. In consequence, previously discrete disciplines-pathology, molecular biology, bioinformatics, and clinical oncology-are converging to deliver integrated care pathways that reduce time to targeted therapy and enable more nuanced patient stratification.

Moreover, the testing landscape is evolving from single-gene assays to multi-gene panels and comprehensive genomic profiling that capture actionable mutations, copy number alterations, and complex genomic signatures. Complementing tissue-based approaches, minimally invasive alternatives such as blood-based testing are accelerating diagnostic workflows and improving patient access to serial monitoring. At the same time, regulatory clarity, payer engagement, and clinical guideline updates are beginning to align, making genomic testing a central component of standard care in many oncology networks. Taken together, these dynamics have created a new operating environment where technological differentiation, evidence generation, and operational resilience determine which organizations lead the next wave of clinical and commercial adoption.

How converging advances in sequencing, liquid biopsy, and digital bioinformatics are rapidly transforming diagnostic pathways and patient management in lung cancer care

The landscape of lung cancer genomic testing is undergoing several transformative shifts driven by advances in assay technology, data analytics, and care delivery models. Most notably, next generation sequencing has evolved from high-cost, research-oriented workflows toward more efficient, clinically validated platforms that support targeted sequencing panels as well as broader coverage through whole exome and whole genome approaches. This progression enables clinicians to detect rare variants and comprehensive genomic signatures while laboratories optimize throughput and turnaround time.

In parallel, liquid biopsy methodologies-encompassing both circulating tumor cells and circulating tumor DNA-are transitioning from complementary tools to integral components of diagnostic and monitoring strategies. These assays offer a less invasive route to capture tumor heterogeneity and to monitor treatment response or emergent resistance. Meanwhile, real time polymerase chain reaction and fluorescence in situ hybridization maintain important roles for specific, rapid biomarker detection, particularly where regulatory or payer frameworks favor established methods.

Concurrently, digital health and AI-driven bioinformatics have matured to support automated variant calling, clinical annotation, and decision support, thereby reducing interpretation bottlenecks and enabling scalable reporting across diverse clinical settings. Regulatory agencies are adapting guidance for companion diagnostics and complex genomic tests, and payers are increasingly evaluating clinical utility and value-based reimbursement pathways. Together, these shifts are creating a more integrated, data-rich ecosystem that rewards evidence generation, interoperability, and operational agility.

How recent tariff-driven supply chain pressures have reshaped procurement, manufacturing strategies, and commercial approaches for genomic diagnostics

Recent tariff adjustments enacted by national policymakers have introduced a renewed emphasis on supply chain resilience and procurement strategy within the diagnostic ecosystem. Because genomic testing relies on a global supply chain for reagents, sequencing instruments, plastic consumables, and specialized microfluidic components, any tariff-driven cost increases reverberate through laboratory operations, reagent procurement cycles, and capital equipment acquisition decisions. As a result, laboratories and diagnostic providers have had to reassess vendor contracts, inventory strategies, and capital planning to preserve service continuity and to maintain acceptable turnaround times.

In response, several stakeholders have explored alternative sourcing and local manufacturing partnerships to mitigate exposure to import levies and shipping volatility. Procurement teams are negotiating longer-term supply agreements and prioritizing suppliers with diversified production footprints to reduce single-source risk. At the same time, diagnostic developers are accelerating work on assay designs that reduce reagent volumes or substitute tariff-sensitive components, thereby lowering the operational impact of import duties.

From a clinical perspective, sustained cost pressure may slow the adoption of more expensive, comprehensive testing in some care settings unless offset by payer coverage or bundled contracting. Consequently, laboratories and device manufacturers are investing in health economic evidence and real-world utility studies to demonstrate cost-effectiveness and inform value-based arrangements. Overall, tariff-driven pressures are catalyzing a strategic reorientation toward supply-chain diversification, localized manufacturing, and commercially sustainable assay design.

Segment-focused insights showing how technology choices, specimen modalities, clinical applications, and end-user capabilities jointly determine adoption pathways and value propositions

A detailed segmentation perspective reveals nuanced adoption patterns across technology, test type, application, and end user categories that are shaping market opportunity and investment priorities. Within the technology dimension, assays range from fluorescence in situ hybridization and microarray platforms to real time polymerase chain reaction and Sanger sequencing; however, next generation sequencing has emerged as a pivotal technology with diverse configurations that include targeted sequencing panels for focused actionable alterations, whole exome sequencing for comprehensive coding-region analysis, and whole genome sequencing for the broadest possible variant detection and structural insight. Each configuration carries distinct trade-offs in sensitivity, breadth of coverage, turnaround time, and interpretive complexity.

Regarding test type, the domain divides between liquid biopsy and tissue biopsy modalities. Liquid biopsy comprises both circulating tumor cells and circulating tumor DNA approaches, offering minimally invasive sampling and superior feasibility for serial monitoring. Tissue biopsy remains essential for histopathologic assessment and includes fine needle aspiration techniques as well as traditional tissue sections used for immunohistochemistry and confirmatory molecular assays. These two sampling paradigms often play complementary roles in the diagnostic pathway, with diagnostic stewardship determining optimal sequencing of tests.

In terms of application, testing supports companion diagnostics that directly guide therapy selection, predictive testing to anticipate treatment response, prognostic testing to inform outcome expectations, and treatment monitoring to detect resistance or recurrence. Adoption intensity varies by clinical setting, evidence base, and payer alignment. Finally, end users encompass academic and research institutes that drive assay validation and translational studies, hospitals and diagnostic laboratories that deliver clinical testing at scale and manage patient workflows, and pharmaceutical and biotechnology companies that rely on robust genomic characterization to support drug development, companion diagnostic partnerships, and patient selection strategies. The interplay among these segments underscores the importance of tailored value propositions, from high-throughput clinical laboratory services to niche translational platforms supporting drug discovery.

Regionally differentiated adoption dynamics and infrastructure considerations that influence technology roll-out, reimbursement engagement, and strategic partnerships

Regional dynamics materially influence technology adoption, regulatory alignment, and commercial strategy, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, a robust ecosystem of academic centers, integrated health systems, and diagnostic innovators has driven early clinical adoption of advanced genomic profiling and liquid biopsy testing. Reimbursement frameworks and large-scale clinical studies in this region have supported the integration of companion diagnostics into therapeutic pathways, while leading laboratories and commercial partners continue to invest in platform scalability and clinical validation programs.

Across Europe, the Middle East and Africa, the landscape is more heterogeneous, characterized by strong regulatory oversight in several countries alongside variability in access and infrastructure. European jurisdictions are increasingly harmonizing regulatory expectations for clinical evidence and companion diagnostics, and collaborative networks are advancing multicenter studies to address clinical utility questions. In contrast, access in some parts of the Middle East and Africa remains constrained by laboratory capacity and reimbursement barriers, prompting a focus on regional centers of excellence and public-private partnerships to extend advanced testing services.

In the Asia-Pacific region, rapid expansion in clinical capacity and manufacturing capabilities is evident alongside diverse payer environments. Several markets demonstrate high adoption rates for both sequencing platforms and liquid biopsy testing, supported by growing local diagnostics industries and targeted investments in genomics. Nevertheless, adoption is uneven, and strategic players often combine centralized high-complexity testing hubs with decentralized sample collection and digital reporting to bridge geographic and resource constraints. These regional distinctions underline the need for market entry strategies that reflect local regulatory processes, reimbursement pathways, and healthcare infrastructure.

How sequencing instrument makers, reagent suppliers, diagnostic laboratories, and biopharma partners are aligning strategies to gain clinical adoption and commercial differentiation

Competitive activity across the lung cancer genomic testing value chain is concentrated among companies that provide sequencing platforms, assay reagents, integrated diagnostic services, and clinical interpretation solutions, as well as among clinical laboratories and diagnostics developers who pair testing with therapeutic programs. Leading instrumentation providers have advanced platform roadmaps focused on throughput, run cost, and integrated analytics, while reagent and kit suppliers compete on robustness, lot-to-lot consistency, and clinical validation packages that simplify regulatory submissions and laboratory accreditation.

Diagnostic laboratories and specialty providers leverage vertical integration, offering end-to-end services from sample accessioning to clinical reporting, often augmenting their offerings with proprietary bioinformatics pipelines and curated variant databases. Pharmaceutical and biotechnology collaborators prioritize partners that can deliver rapid, reproducible genomic characterization to support patient selection in trials and companion diagnostic co-development. Strategic moves such as partnerships, distribution agreements, and targeted acquisitions are common as companies seek to broaden assay portfolios, enhance geographic footprint, and reduce time to market for diagnostic claims.

To remain competitive, organizations increasingly invest in real-world evidence generation, payor engagement, and interoperability with electronic health records to demonstrate clinical utility and to facilitate clinician adoption. Additionally, companies that offer scalable, cloud-enabled interpretation tools and that maintain high standards for clinical validation are best positioned to capture demand from both centralized reference laboratories and decentralized hospital networks.

Action-oriented recommendations for companies to strengthen supply resilience, accelerate evidence generation, and secure payer and partner alignment for sustainable growth

Industry leaders should prioritize a set of pragmatic, evidence-based actions to navigate technological complexity, policy shifts, and market pressures while capturing clinical and commercial value. First, diversify supply chains and pursue localized manufacturing or second-source agreements for tariff-sensitive reagents and consumables to reduce single-point vulnerabilities and to stabilize procurement costs. Parallel to this, invest in assay optimization that minimizes reagent volumes and streamlines workflows to preserve margins and resilience.

Second, accelerate clinical validation and real-world evidence programs that demonstrate clinical utility and health economic value. Robust outcome datasets will strengthen reimbursement negotiations and support placement of comprehensive genomic profiling in standard care pathways. Third, expand capabilities in bioinformatics and AI-driven interpretation to shorten report turnaround time, improve variant classification consistency, and enable scalable clinical decision support that integrates with electronic health systems. Fourth, cultivate payer relationships and explore value-based contracting that ties reimbursement to demonstrable clinical outcomes, thereby aligning incentives across stakeholders.

Fifth, form strategic partnerships with pharmaceutical developers to co-develop companion diagnostics and to secure trial enrollment through biomarker-driven screening. Finally, tailor market access strategies regionally by aligning product claims and evidence packages with local regulatory expectations and by deploying hybrid models that combine centralized high-complexity testing with facilitated sample logistics and remote reporting to broaden access.

A transparent multi-method research approach combining primary expert engagement and systematic evidence review to ensure rigorous and actionable insights

The research underlying this analysis employed a multi-method approach that combined primary qualitative inquiry with systematic secondary intelligence to build a robust and triangulated evidence base. Primary research included structured interviews with clinical laboratory directors, molecular pathologists, reimbursement specialists, diagnostic developers, and pharmaceutical R&D leaders, supplemented by expert panel discussions to validate emerging trends and practical challenges in assay deployment. These engagements provided granular insight into laboratory workflows, procurement dynamics, and the operational impact of regulatory and tariff changes.

Secondary research entailed a rigorous review of regulatory guidance documents, clinical practice recommendations, peer-reviewed literature on assay performance and utility, and corporate disclosures that elucidate strategic priorities and product capabilities. Data synthesis prioritized high-quality clinical validation studies and real-world evidence where available. All findings were cross-validated through triangulation to reconcile differing perspectives and to ensure that conclusions reflect consistent signals rather than isolated observations.

Where appropriate, analytical safeguards were applied to account for variability in care settings and regional policy environments. Methodological limitations were explicitly noted, particularly where evidence remains nascent or practice patterns are rapidly evolving. The research adhered to ethical standards for expert engagement and data handling, ensuring confidentiality and the integrity of qualitative insights.

A concise synthesis of how technological advances and strategic imperatives must be aligned to translate genomic testing into durable clinical and commercial impact

The convergence of advanced sequencing technologies, liquid biopsy innovations, and digital interpretation tools has irreversibly altered the clinical landscape for lung cancer genomic testing. These developments present both opportunities and challenges: opportunities to enable more precise treatment selection, to support adaptive clinical trials, and to deliver longitudinal monitoring with minimally invasive tests; and challenges in supply-chain management, evidence generation, and payer engagement that require strategic foresight. Decision-makers must therefore adopt an integrated view that aligns technological investment, clinical validation, and commercial pathways.

Effective responses will blend operational resilience with evidence-led commercialization. By diversifying supply sources, investing in compact and cost-efficient assays, and demonstrating clinical and economic value through robust studies, stakeholders can reduce exposure to policy and market shocks while accelerating adoption. At the same time, regionally nuanced strategies that respect local regulatory norms and healthcare infrastructures will be essential for converting global potential into sustainable clinical impact. In sum, the era of precision oncology in lung cancer depends on harmonized action across industry, clinical, and regulatory stakeholders to translate technical capability into improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Genomic Testing Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Microarray
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Whole Exome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Real Time Polymerase Chain Reaction
  • 8.5. Sanger Sequencing

9. Lung Cancer Genomic Testing Market, by Test Type

  • 9.1. Liquid Biopsy
    • 9.1.1. Circulating Tumor Cells
    • 9.1.2. Circulating Tumor Dna
  • 9.2. Tissue Biopsy
    • 9.2.1. Fine Needle Aspiration
    • 9.2.2. Tissue Section

10. Lung Cancer Genomic Testing Market, by Application

  • 10.1. Companion Diagnostics
  • 10.2. Predictive Testing
  • 10.3. Prognostic Testing
  • 10.4. Treatment Monitoring

11. Lung Cancer Genomic Testing Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Hospitals And Diagnostic Laboratories
  • 11.3. Pharmaceutical And Biotechnology Companies

12. Lung Cancer Genomic Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Lung Cancer Genomic Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Lung Cancer Genomic Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Lung Cancer Genomic Testing Market

16. China Lung Cancer Genomic Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Admera Health
  • 17.7. Agilent Technologies, Inc.
  • 17.8. BGI
  • 17.9. CD Genomics
  • 17.10. CeGaT GmbH
  • 17.11. Centogene N.V.
  • 17.12. F. Hoffmann-La Roche AG
  • 17.13. Illumina, Inc.
  • 17.14. Laboratory Corporation of America Holdings
  • 17.15. NeoGenomics Laboratories
  • 17.16. OncoDNA
  • 17.17. OPKO Health, Inc.
  • 17.18. QIAGEN N.V.
  • 17.19. Quest Diagnostics Incorporated
  • 17.20. Thermo Fisher Scientific, Inc.
  • 17.21. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 149. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 152. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 173. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 176. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 181. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 183. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)